Harvard Study: Half of Adult Americans Eligible for Ozempic-Like Drugs
From Dr. Peter McCullough MD
By Peter A. McCullough, MD, MPH Glucagon-like peptide receptor agonists (GLP-1 RA) are the current financial rainmakers for BIG PHARMA. Shi et al from Harvard reported recently in JAMA Cardiology. Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion. Quantifying the number of […]
Nov 20th 2024 5:02am EST
Source Link: https://petermcculloughmd.substack.com/p/harvard-study-half-of-adult-americans
Share, promote & comment with Nostr: https://dissentwatch.com/boost/?boost_post_id=878237
DissentWatch
npub1mx…gfcal
2024-11-20 10:30:39
Author Public Key
npub1mxq4j8sw5c2nhp58k2hdvu9t0kdkcwksrz3kpv5zpv70pa7q4cmsqgfcalPublished at
2024-11-20 10:30:39Event JSON
{
"id": "ae6c94e3ea8e57eed002e8c988e1de8224cd06f8e4541d846bd4610cb52d6e71",
"pubkey": "d981591e0ea6153b8687b2aed670ab7d9b6c3ad018a360b2820b3cf0f7c0ae37",
"created_at": 1732098639,
"kind": 1,
"tags": [],
"content": "Harvard Study: Half of Adult Americans Eligible for Ozempic-Like Drugs\n\nFrom Dr. Peter McCullough MD\n\nBy Peter A. McCullough, MD, MPH Glucagon-like peptide receptor agonists (GLP-1 RA) are the current financial rainmakers for BIG PHARMA. Shi et al from Harvard reported recently in JAMA Cardiology. Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion. Quantifying the number of […]\n\nNov 20th 2024 5:02am EST\n\nSource Link: https://petermcculloughmd.substack.com/p/harvard-study-half-of-adult-americans\n\nShare, promote \u0026 comment with Nostr: https://dissentwatch.com/boost/?boost_post_id=878237",
"sig": "1cfd34814187d1d45be404676d7d0370176b7f21051648f8b1a5eabd4b6704c34f6695877276f95cb8e7865e65a12c1553ad996c8acd04ad1ad34c0e4321a272"
}